SG Americas Securities’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.35M | Buy |
85,892
+3,410
| +4% | +$110K | ﹤0.01% | 1267 |
|
|
2026
Q1 | $2.68M | Buy |
82,482
+12,869
| +18% | +$414K | ﹤0.01% | 1262 |
|
|
2025
Q4 | $2.45M | Sell |
69,613
-26,191
| -27% | -$928K | ﹤0.01% | 1408 |
|
|
2025
Q3 | $2.52M | Buy |
95,804
+81,519
| +571% | +$2.43M | 0.01% | 829 |
|
|
2025
Q2 | $379K | Buy |
+14,285
| New | +$376K | ﹤0.01% | 1844 |
|
|
2025
Q1 | – | Sell |
-23,552
| Closed | -$948K | – | 3782 |
|
|
2024
Q4 | $948K | Buy |
23,552
+15,049
| +177% | +$858K | ﹤0.01% | 891 |
|
|
2024
Q3 | $538K | Sell |
8,503
-81,116
| -91% | -$4.76M | ﹤0.01% | 1626 |
|
|
2024
Q2 | $4.75M | Buy |
89,619
+64,079
| +251% | +$4.2M | 0.03% | 564 |
|
|
2024
Q1 | $2.09M | Sell |
25,540
-5,953
| -19% | -$265K | 0.01% | 850 |
|
|
2023
Q4 | $586K | Sell |
31,493
-50,606
| -62% | -$662K | 0.01% | 1376 |
|
|
2023
Q3 | $909K | Buy |
82,099
+74,085
| +924% | +$1.06M | 0.01% | 1347 |
|
|
2023
Q2 | $130K | Buy |
+8,014
| New | +$168K | ﹤0.01% | 1982 |
|
|
2023
Q1 | – | Sell |
-10,684
| Closed | -$100K | – | 3580 |
|
|
2022
Q4 | $100K | Buy |
+10,684
| New | +$47.7K | ﹤0.01% | 2726 |
|
|
2022
Q2 | – | Sell |
-78,850
| Closed | -$237K | – | 3630 |
|
|
2022
Q1 | $237K | Sell |
78,850
-12,947
| -14% | -$46.4K | ﹤0.01% | 2330 |
|
|
2021
Q4 | $422K | Sell |
91,797
-6,212
| -6% | -$34.8K | ﹤0.01% | 2260 |
|
|
2021
Q3 | $615K | Buy |
98,009
+85,882
| +708% | +$531K | ﹤0.01% | 2326 |
|
|
2021
Q2 | $73K | Buy |
+12,127
| New | +$72K | ﹤0.01% | 2715 |
|
|
2021
Q1 | – | Sell |
-126,106
| Closed | -$710K | – | 3582 |
|
|
2020
Q4 | $710K | Sell |
126,106
-177,122
| -58% | -$1.07M | ﹤0.01% | 1735 |
|
|
2020
Q3 | $1.76M | Buy |
303,228
+234,288
| +340% | +$1.61M | 0.01% | 821 |
|
|
2020
Q2 | $497K | Sell |
68,940
-104,792
| -60% | -$696K | ﹤0.01% | 2103 |
|
|
2020
Q1 | $813K | Buy |
173,732
+113,766
| +190% | +$699K | 0.01% | 1444 |
|
|
2019
Q4 | $481K | Sell |
59,966
-190,918
| -76% | -$1.39M | ﹤0.01% | 1826 |
|
|
2019
Q3 | $1.73M | Buy |
250,884
+224,456
| +849% | +$1.67M | 0.01% | 1055 |
|
|
2019
Q2 | $219K | Buy |
+26,428
| New | +$226K | ﹤0.01% | 2370 |
|
|
2019
Q1 | – | Sell |
-16,221
| Closed | -$124K | – | 3654 |
|
|
2018
Q4 | $124K | Sell |
16,221
-13,954
| -46% | -$167K | ﹤0.01% | 2612 |
|
|
2018
Q3 | $526K | Buy |
+30,175
| New | +$359K | ﹤0.01% | 2083 |
|
Other funds holding VKTX
SG Americas Securities's VKTX Position: Q2 2026 in Review
SG Americas Securities increased its Viking Therapeutics (VKTX) stake by 4.1% in Q2 2026, buying an estimated $110K and bringing the position to 85,892 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1267.
SG Americas Securities first reported a position in VKTX in Q3 2018 and has held it in 26 quarters since. The position peaked at $4.75M in Q2 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- SG Americas Securities held 85,892 shares of Viking Therapeutics worth $3.35M as of Q2 2026.
- SG Americas Securities bought 3,410 Viking Therapeutics shares in Q2 2026, an estimated $110K.
- Viking Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1267 holding.
- SG Americas Securities first reported a position in Viking Therapeutics in Q3 2018 and has held it in 26 quarters since.
- SG Americas Securities's Viking Therapeutics position peaked at $4.75M in Q2 2024.
- 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.